Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide. The company operates through two segments, Drug Development and Chromatography. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA HPLC analytical columns. The company provides products for the analysis and purification of substances, with a focus on peptides and diabetes drugs. In addition, it is involved in the development of nanoporous amorphous particles (NAP), a platform technology for inhalation to give access to new or enhanced treatments for the patients with severe lung diseases. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.